Where Asymmetric dimethylarginine (ADMA) is reported
Also listed as: NO synthase inhibitor
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↑ elevated | healthy controls | Reduced NO bioavailability | Thomas et al. 2024 |
Frequently asked questions
In which conditions is Asymmetric dimethylarginine (ADMA) altered?
In the OSMF atlas Asymmetric dimethylarginine (ADMA) is reported in Long COVID. It is elevated in 1 across 1 entries.
What is the LOINC code for Asymmetric dimethylarginine (ADMA)?
Entries in this atlas use LOINC 10988-1. LOINC codes identify the laboratory observation so results can be compared across systems.
Is one abnormal Asymmetric dimethylarginine (ADMA) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Open Source Medicine Foundation. (2026). Asymmetric dimethylarginine (ADMA) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/asymmetric-dimethylarginine-adma.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack
Subscribe on Substack
Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.